Abstract
Cell-Free Therapies hBMMSC-apoVs can promote mesenchymal stem cell (MSC) osteogenesis and inhibit osteoclast formation in vitro and in vivo. The mechanisms include the release of miR1324, which inhibits the expression of the target gene SNX14, thereby activating the SMAD1/5 pathway in target cells. In article number 2205813, Xiao Zhang, Yunsong Liu, and co-workers suggest a therapeutic strategy for the treatment of bone loss, including bone tissue engineering through a cell-free approach.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
